JOHNSON & JOHNSON is 5.2x more valuable than VERTEX PHARMACEUTICALS INC / MA by market capitalization ($573.98 B vs $110.46 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VRTX | JNJ |
|---|---|---|
| Market cap | $110.46 B | $573.98 B |
| US-listed rank | #136 | #20 |
| Revenue (latest FY) | $12.00B | $94.19B |
| Net income (latest FY) | $3.95B | $26.80B |
| Net margin | 32.9% | 28.5% |
| P/E (trailing FY) | 27.9 | 21.4 |
| SEC filings | 1,000 | 984 |
JOHNSON & JOHNSON is 5.2x more valuable than VERTEX PHARMACEUTICALS INC / MA by market capitalization ($573.98 B vs $110.46 B).
In their latest fiscal years, VERTEX PHARMACEUTICALS INC / MA reported $12.00B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: VERTEX PHARMACEUTICALS INC / MA and JOHNSON & JOHNSON, or browse the full rankings.